ELSPAR Side Effects

7027421-5 | Cerebral Infarction, Convulsion, Haemorrhagic Infarction, Headache, Loss Of Consciousness, Superior Sagittal Sinus Thrombosis, Vomiting
on Sep 20, 2010 Male patient from INDIA , child 10 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral infarction, convulsion, haemorrhagic infarction, headache (What is headache?), loss of consciousness, superior sagittal sinus thrombosis, vomiting. Elspar dosage: Intravenous. During the same period patient was treated with VINCRISTINE (Intravenous) (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (Intravenous) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISOLONE (Oral) (View Prednisolone Review and Prednisolone Label ), METHOTREXATE (Intrathecal) (View Methotrexate Review and Methotrexate Label ).

6925796-6 | Body Temperature Increased, Haemoglobin Decreased, Neutrophil Percentage Increased, Pneumatosis Intestinalis
Patient was taking Elspar (View Usage). Patient had the following side effects: body temperature increased, haemoglobin decreased, neutrophil percentage increased, pneumatosis intestinalis on Jul 30, 2010 from NETHERLANDS Additional patient health information: Female patient , child 2. years of age, was diagnosed with acute lymphocytic leukaemia and. Elspar dosage: Intravenous. During the same period patient was treated with PREDNISONE (Oral) (View Prednisone Review and Prednisone Label ), DAUNORUBICIN HCL (Intravenous) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), VINCRISTINE (Intravenous Bolus) (View Vincristine Review and Vincristine Label ), CIPROXIN (CIPROFLOXACIN) (View Ciproxin (ciprofloxacin) Review and Ciproxin (ciprofloxacin) Label ), BACTRIM (View Bactrim Review and Bactrim Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ).

6840239-9 | Rash Pruritic
Adverse event was reported on Jul 13, 2010 by a Female patient taking Elspar (View Usage) (Dosage: 6000 Units/ M2 Once Im) was diagnosed with acute myeloid leukaemia and. Location: UNITED STATES , weighting 105.8 lb, After Elspar was administered, patient had the following side effects: rash pruritic. Patient was hospitalized.

6786897-9 | Blood Calcium Increased, Depressed Level Of Consciousness, Infection, Productive Cough, Pulmonary Alveolar Microlithiasis, Pulmonary Calcification, Respiratory Distress, Vomiting
on Jun 09, 2010 Female patient from IRAN (ISLAMIC REPUBLIC OF) , child 4 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: blood calcium increased, depressed level of consciousness, infection (What is infection?), productive cough, pulmonary alveolar microlithiasis, pulmonary calcification, respiratory distress, vomiting. Elspar dosage: X9. During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), VINCRISTINE (X4) (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), METHOTREXATE (500 Mg/m2 Milligram(s)/ Sq.) (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (X2) (View Cyclophosphamide Review and Cyclophosphamide Label ), CYTARABINE (X12) (View Cytarabine Review and Cytarabine Label ).


6761430-6 | Blood Calcium Increased, Calcification Metastatic, Depressed Level Of Consciousness, Pulmonary Alveolar Microlithiasis, Pulmonary Calcification, Respiratory Distress, Vomiting
on May 24, 2010 Female patient from IRAN (ISLAMIC REPUBLIC OF) , child 4 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient had the following side effects: blood calcium increased, calcification metastatic, depressed level of consciousness, pulmonary alveolar microlithiasis, pulmonary calcification, respiratory distress, vomiting. Elspar dosage: X9. During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), VINCRISTINE (X4) (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), METHOTREXATE (500 Mg/m2 Milligram(s)/sq.meter, Intravenous (not Otherwise Specified)) (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (X2) (View Cyclophosphamide Review and Cyclophosphamide Label ), CYTARABINE (X12) (View Cytarabine Review and Cytarabine Label ).

6698901-7 | Blister, Injection Site Erythema, Injection Site Induration, Injection Site Pain, Pigmentation Disorder, Purulence
Patient was taking Elspar (View Usage). After Elspar was administered, patient had the following side effects: blister, injection site erythema, injection site induration, injection site pain, pigmentation disorder, purulence on Apr 26, 2010 from UNITED STATES Additional patient health information: Male patient , 46 years of age, weighting 224.0 lb, was diagnosed with lymphoma (What is lymphoma?) and. Elspar dosage: 13,800 Units Twice Weekly Sq.

6589491-8 | Blood Pressure Increased, Grand Mal Convulsion, Reversible Posterior Leukoencephalopathy Syndrome
Adverse event was reported on Jan 27, 2010 by a Female patient taking Elspar (View Usage) (Dosage: ) was diagnosed with chronic myeloid leukaemia and. Location: INDIA , child 9 years of age, Patient experienced the following unwanted or unexpected effects: blood pressure increased, grand mal convulsion, reversible posterior leukoencephalopathy syndrome. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ). Patient was hospitalized.

6580199-1 | Brain Oedema, Cerebral Infarction, Pneumonia, Respiratory Failure, Superior Sagittal Sinus Thrombosis
on Jan 21, 2010 Female patient from UNITED KINGDOM , 73 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient had the following side effects: brain oedema, cerebral infarction, pneumonia (What is pneumonia?), respiratory failure, superior sagittal sinus thrombosis. Elspar dosage: . During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ). Patient was hospitalized.

6558260-7 | Hyperglycaemia, Pancreatic Pseudocyst, Pancreatitis
on Jan 14, 2010 Female patient from UNITED STATES , child 4 years of age, was diagnosed with b-cell type acute leukaemia and was treated with Elspar (View Usage). After Elspar was administered, patient had the following side effects: hyperglycaemia, pancreatic pseudocyst, pancreatitis. Elspar dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ). Patient was hospitalized.

6558256-5 | Pancreatic Pseudocyst, Pancreatitis Acute
Patient was taking Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: pancreatic pseudocyst, pancreatitis acute on Jan 14, 2010 from UNITED STATES Additional patient health information: Male patient , 15 years of age, was diagnosed with t-cell type acute leukaemia and. Elspar dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ).

6558253-X | Pancreatic Atrophy, Pancreatic Pseudocyst, Pancreatitis Acute
Adverse event was reported on Jan 14, 2010 by a Male patient taking Elspar (View Usage) (Dosage: ) was diagnosed with t-cell type acute leukaemia and. Location: UNITED STATES , 17 years of age, Patient had the following side effects: pancreatic atrophy, pancreatic pseudocyst, pancreatitis acute. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ). Patient was hospitalized.

6536525-2 | Blood Glucose Increased, Headache, Hypercholesterolaemia, Hypertriglyceridaemia, Pain, Pyrexia
on Dec 21, 2009 Male patient from INDIA , 42 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). After Elspar was administered, patient had the following side effects: blood glucose increased, headache (What is headache?), hypercholesterolaemia, hypertriglyceridaemia, pain (What is pain?), pyrexia. Elspar dosage: ; Qod;. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), DAUNOMYCIN (View Daunomycin Review and Daunomycin Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6456632-2 | Antithrombin Iii Decreased, Cerebral Haemorrhage, Convulsion, Haemoglobin Decreased, Ischaemic Stroke, Platelet Count Decreased, Protein C Increased, Red Blood Cell Count Decreased, White Blood Cell Count Decreased
on Nov 04, 2009 Male patient from UNITED STATES , 17 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: antithrombin iii decreased, cerebral haemorrhage, convulsion, haemoglobin decreased, ischaemic stroke, platelet count decreased, protein c increased, red blood cell count decreased, white blood cell count decreased. Elspar dosage: Iv ; Iv. During the same period patient was treated with PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ).

6456629-2 | Alpha Haemolytic Streptococcal Infection, Antithrombin Iii Decreased, Candidiasis, Grand Mal Convulsion, Ischaemic Stroke, Loss Of Consciousness, Pancytopenia, Staphylococcal Infection
Patient was taking Elspar (View Usage). Patient had the following side effects: alpha haemolytic streptococcal infection, antithrombin iii decreased, candidiasis, grand mal convulsion, ischaemic stroke, loss of consciousness, pancytopenia, staphylococcal infection (What is staphylococcal infection?) on Nov 04, 2009 from UNITED STATES Additional patient health information: Male patient , child 9 years of age, was diagnosed with acute lymphocytic leukaemia and. Elspar dosage: . During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ).

6432126-5 | Reversible Posterior Leukoencephalopathy Syndrome
Adverse event was reported on Oct 23, 2009 by a Female patient taking Elspar (View Usage) (Dosage: ) was diagnosed with myeloid leukaemia and. Location: TURKEY , 20 years of age, After Elspar was administered, patient had the following side effects: reversible posterior leukoencephalopathy syndrome. During the same period patient was treated with METHOTREXATE (Iv) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ).

6401763-6 | Neutropenia, Pancreatic Pseudocyst, Pancreatitis Acute, Pneumonia, Pseudomonas Infection
on Sep 29, 2009 Female patient from POLAND , child 4 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: neutropenia, pancreatic pseudocyst, pancreatitis acute, pneumonia (What is pneumonia?), pseudomonas infection. Elspar dosage: . Patient was hospitalized.

6401754-5 | Circulatory Collapse, Disease Complication, Multi-organ Disorder, Pancreatic Pseudocyst, Pancreatitis Acute, Shock, Staphylococcal Infection
on Sep 29, 2009 Female patient from POLAND , child 2 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient had the following side effects: circulatory collapse, disease complication, multi-organ disorder, pancreatic pseudocyst, pancreatitis acute, shock, staphylococcal infection (What is staphylococcal infection?). Elspar dosage: . Patient was hospitalized.

6250001-6 | Alanine Aminotransferase Increased, Ammonia Increased, Arrhythmia, Aspartate Aminotransferase Increased, Blood Lactate Dehydrogenase Increased, Hypertension, Hyperventilation, Presyncope
Patient was taking Elspar (View Usage). After Elspar was administered, patient had the following side effects: alanine aminotransferase increased, ammonia increased, arrhythmia (What is arrhythmia?), aspartate aminotransferase increased, blood lactate dehydrogenase increased, hypertension, hyperventilation, presyncope on Jun 17, 2009 from UNITED STATES Additional patient health information: Female patient , 14 years of age, was diagnosed with leukaemia and. Elspar dosage: . During the same period patient was treated with DASATINIB (NO PREF. NAME) (160 Mg; Qd; Po) (View Dasatinib (no Pref. Name) Review and Dasatinib (no Pref. Name) Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), MTX (View Mtx Review and Mtx Label ). Patient was hospitalized.

6242072-8 | Alanine Aminotransferase Decreased, Ammonia Increased, Arrhythmia, Aspartate Aminotransferase Increased, Blood Lactate Dehydrogenase Increased, Hypertension, Hyperventilation, Laboratory Test Interference, Presyncope
Adverse event was reported on May 18, 2009 by a Female patient taking Elspar (View Usage) (Dosage: ) was diagnosed with leukaemia and. Location: UNITED STATES , 14 years of age, Patient experienced the following unwanted or unexpected effects: alanine aminotransferase decreased, ammonia increased, arrhythmia (What is arrhythmia?), aspartate aminotransferase increased, blood lactate dehydrogenase increased, hypertension, hyperventilation, laboratory test interference, presyncope. During the same period patient was treated with DASATINIB (NO PREF. NAME) (160 Mg;qd;po) (View Dasatinib (no Pref. Name) Review and Dasatinib (no Pref. Name) Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), MTX (View Mtx Review and Mtx Label ). Patient was hospitalized.

6140102-5 | Abdominal Rigidity, Activated Partial Thromboplastin Time Prolonged, Ascites, Blood Bilirubin Increased, Blood Bilirubin Unconjugated Increased, Blood Lactate Dehydrogenase Increased, Haemoglobin Decreased, Leukaemia Cutis, Pancreatitis Acute
on Mar 12, 2009 Male patient from UNITED STATES , child 7 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient had the following side effects: abdominal rigidity, activated partial thromboplastin time prolonged, ascites, blood bilirubin increased, blood bilirubin unconjugated increased, blood lactate dehydrogenase increased, haemoglobin decreased, leukaemia cutis, pancreatitis acute. Elspar dosage: ; Tiw; Iv. During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6120922-3 | Acquired Protein S Deficiency, Antithrombin Iii Deficiency, Cerebral Thrombosis, Platelet Count Decreased, Protein C Deficiency
on Feb 23, 2009 Male patient from BELGIUM , 17 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). After Elspar was administered, patient had the following side effects: acquired protein s deficiency, antithrombin iii deficiency, cerebral thrombosis, platelet count decreased, protein c deficiency. Elspar dosage: . During the same period patient was treated with METHYLPREDNISOLONE 16MG TAB (View Methylprednisolone 16mg Tab Review and Methylprednisolone 16mg Tab Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6097142-4 | Cerebral Venous Thrombosis
Patient was taking Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral venous thrombosis on Feb 10, 2009 from BELGIUM Additional patient health information: Male patient , 17 years of age, was diagnosed with acute lymphocytic leukaemia and. Elspar dosage: .

5942634-9 | Large Intestine Perforation, Neutropenic Colitis, Platelet Count Increased, Post Procedural Infection
Adverse event was reported on Oct 16, 2008 by a Female patient taking Elspar (View Usage) (Dosage: ) was diagnosed with acute lymphocytic leukaemia and. Location: ITALY , 38 years of age, Patient had the following side effects: large intestine perforation, neutropenic colitis, platelet count increased, post procedural infection. During the same period patient was treated with DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ). Patient was hospitalized.

5921267-4 | Encephalopathy, Gaze Palsy, Grand Mal Convulsion, Mydriasis
on Sep 29, 2008 Male patient from UNITED STATES , child 4 years of age, was diagnosed with t-cell type acute leukaemia and was treated with Elspar (View Usage). After Elspar was administered, patient had the following side effects: encephalopathy, gaze palsy, grand mal convulsion, mydriasis. Elspar dosage: . During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ).

5921265-0 | Cerebrosclerosis, Electroencephalogram Abnormal, Encephalopathy, Gaze Palsy, Grand Mal Convulsion, Hypertension, Nuclear Magnetic Resonance Imaging Abnormal, Temporal Lobe Epilepsy, Visual Impairment
on Sep 29, 2008 Female patient from UNITED STATES , child 5 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: cerebrosclerosis, electroencephalogram abnormal, encephalopathy, gaze palsy, grand mal convulsion, hypertension, nuclear magnetic resonance imaging abnormal, temporal lobe epilepsy, visual impairment. Elspar dosage: . During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ).

5913940-9 | Encephalopathy
Patient was taking Elspar (View Usage). Patient had the following side effects: encephalopathy on Sep 29, 2008 from ITALY Additional patient health information: Male patient , child 4 years of age, was diagnosed with acute lymphocytic leukaemia and. Elspar dosage: . During the same period patient was treated with DECADRON (View Decadron Review and Decadron Label ), DOXORUBICIN (View Doxorubicin Review and Doxorubicin Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ).

5913936-7 | Convulsion, Encephalopathy, Temporal Lobe Epilepsy
Adverse event was reported on Sep 29, 2008 by a Male patient taking Elspar (View Usage) (Dosage: ) . Location: ITALY , child 4 years of age, After Elspar was administered, patient had the following side effects: convulsion, encephalopathy, temporal lobe epilepsy. During the same period patient was treated with DECADRON (View Decadron Review and Decadron Label ), DOXORUBICIN (View Doxorubicin Review and Doxorubicin Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ).

5872248-0 | B Precursor Type Acute Leukaemia, Neutropenia, Sepsis
on Aug 25, 2008 Female patient from UNITED STATES , 30 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: b precursor type acute leukaemia, neutropenia, sepsis (What is sepsis?). Elspar dosage: . During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), DECADRON SRC (View Decadron Src Review and Decadron Src Label ).

5851865-8 | Blood Cholesterol Increased, Diarrhoea Haemorrhagic, Hepatic Steatosis, Hypertriglyceridaemia, Pancreatitis Acute, Pitting Oedema, Respiratory Rate Increased, Tachycardia
on Aug 06, 2008 Male patient from LEBANON , 34 years of age, was diagnosed with non-hodgkin's lymphoma, t-cell lymphoma and was treated with Elspar (View Usage). Patient had the following side effects: blood cholesterol increased, diarrhoea haemorrhagic, hepatic steatosis, hypertriglyceridaemia, pancreatitis acute, pitting oedema, respiratory rate increased, tachycardia. Elspar dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ). Patient was hospitalized.

5842957-8 | Bacterial Disease Carrier, Culture Positive, Eschar, Excoriation, Fall, Klebsiella Bacteraemia, Local Swelling, Neutropenia, Osteomyelitis Fungal
Patient was taking Elspar (View Usage). After Elspar was administered, patient had the following side effects: bacterial disease carrier, culture positive, eschar, excoriation, fall (What is fall?), klebsiella bacteraemia, local swelling, neutropenia, osteomyelitis fungal on Jul 28, 2008 from UNITED STATES Additional patient health information: Male patient , child 10 years of age, was diagnosed with acute myeloid leukaemia and. Elspar dosage: . During the same period patient was treated with ARA C (View Ara-c Review and Ara-c Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), MITROXANATE (View Mitroxanate Review and Mitroxanate Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), INTRATHECAL ARA C (View Intrathecal Ara-c Review and Intrathecal Ara-c Label ). Patient was hospitalized.

5828783-4 | Atonic Urinary Bladder, Febrile Neutropenia, Grand Mal Convulsion, Ileus Paralytic, Neuropathy Peripheral, Reversible Posterior Leukoencephalopathy Syndrome
Adverse event was reported on Jul 17, 2008 by a Female patient taking Elspar (View Usage) (Dosage: ) was diagnosed with b precursor type acute leukaemia, febrile neutropenia and. Location: INDIA , child 11 years of age, Patient experienced the following unwanted or unexpected effects: atonic urinary bladder, febrile neutropenia, grand mal convulsion, ileus paralytic, neuropathy peripheral, reversible posterior leukoencephalopathy syndrome. During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DAUNORUBICIN (View Daunorubicin Review and Daunorubicin Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), PRIMAXIN (View Primaxin Review and Primaxin Label ).

5828766-4 | Febrile Neutropenia, Ileus Paralytic, Reversible Posterior Leukoencephalopathy Syndrome, Tumour Lysis Syndrome
on Jul 17, 2008 Male patient from INDIA , child 9 years of age, was diagnosed with b precursor type acute leukaemia, febrile neutropenia and was treated with Elspar (View Usage). Patient had the following side effects: febrile neutropenia, ileus paralytic, reversible posterior leukoencephalopathy syndrome, tumour lysis syndrome. Elspar dosage: . During the same period patient was treated with DAUNORUBICIN (View Daunorubicin Review and Daunorubicin Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), PRIMAXIN (View Primaxin Review and Primaxin Label ).

5765220-2 | Acute Lymphocytic Leukaemia Recurrent, Bone Marrow Transplant, Cardiomegaly, Dyspnoea Exertional, Oedema Peripheral, Productive Cough, Pulmonary Hypertension, Venoocclusive Disease, Venous Pressure Jugular Increased
on May 23, 2008 Male patient from UNITED STATES , 24 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). After Elspar was administered, patient had the following side effects: acute lymphocytic leukaemia recurrent, bone marrow transplant (What is bone marrow transplant?), cardiomegaly, dyspnoea exertional, oedema peripheral, productive cough, pulmonary hypertension (What is pulmonary hypertension?), venoocclusive disease, venous pressure jugular increased. Elspar dosage: . During the same period patient was treated with DACTINOMYCIN (View Dactinomycin Review and Dactinomycin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ARABINOSYLCYTOSINE (View Arabinosylcytosine Review and Arabinosylcytosine Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

5764173-0 | Cystitis Haemorrhagic, Leukaemia Recurrent, Mucosal Inflammation, Pulmonary Veno-occlusive Disease, Venoocclusive Liver Disease
Patient was taking Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: cystitis haemorrhagic, leukaemia recurrent, mucosal inflammation, pulmonary veno-occlusive disease, venoocclusive liver disease on May 23, 2008 from UNITED STATES Additional patient health information: Male patient , child 4 years of age, was diagnosed with acute lymphocytic leukaemia and. Elspar dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), TENEPOSIDE (View Teneposide Review and Teneposide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

5764172-9 | Acute Lymphocytic Leukaemia Recurrent, Bone Marrow Transplant, Chronic Graft Versus Host Disease, No Therapeutic Response, Post Procedural Complication, Pulmonary Veno-occlusive Disease, Stomatitis
Adverse event was reported on May 23, 2008 by a Female patient taking Elspar (View Usage) (Dosage: ) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , child 4 years of age, Patient had the following side effects: acute lymphocytic leukaemia recurrent, bone marrow transplant (What is bone marrow transplant?), chronic graft versus host disease, no therapeutic response, post procedural complication, pulmonary veno-occlusive disease, stomatitis. During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), DAUNOMYCIN (View Daunomycin Review and Daunomycin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

5757806-6 | Superior Sagittal Sinus Thrombosis
on May 16, 2008 Male patient from UNITED STATES , 36 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). After Elspar was administered, patient had the following side effects: superior sagittal sinus thrombosis. Elspar dosage: . Patient was hospitalized.

5757805-4 | Superior Sagittal Sinus Thrombosis
on May 16, 2008 Female patient from UNITED STATES , 40 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: superior sagittal sinus thrombosis. Elspar dosage: . Patient was hospitalized.

5731142-6 | Acanthamoeba Infection, Acute Lymphocytic Leukaemia, Diarrhoea, Hemiparesis, Jaundice, Malignant Neoplasm Progression, Meningoencephalitis Amoebic, Partial Seizures
Patient was taking Elspar (View Usage). Patient had the following side effects: acanthamoeba infection, acute lymphocytic leukaemia, diarrhoea, hemiparesis, jaundice (What is jaundice?), malignant neoplasm progression, meningoencephalitis amoebic, partial seizures on Apr 21, 2008 from UNITED STATES Additional patient health information: Male patient , 17 years of age, was diagnosed with acute lymphocytic leukaemia and. Elspar dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), DAUNORUBICN (DAUNORUBICN) (View Daunorubicn (daunorubicn) Review and Daunorubicn (daunorubicn) Label ), STEROIDS (NO PREF. NAME) (View Steroids (no Pref. Name) Review and Steroids (no Pref. Name) Label ). Patient was hospitalized.

5731093-7 | Dehydration, Diabetic Ketoacidosis, Hyperphagia, Hypoglycaemia
Adverse event was reported on Apr 21, 2008 by a Female patient taking Elspar (View Usage) (Dosage: ) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , child 10 years of age, After Elspar was administered, patient had the following side effects: dehydration, diabetic ketoacidosis, hyperphagia, hypoglycaemia. Patient was hospitalized.

5731092-5 | Dehydration, Diabetic Ketoacidosis
on Apr 21, 2008 Male patient from UNITED STATES , 16 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: dehydration, diabetic ketoacidosis. Elspar dosage: . During the same period patient was treated with PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ). Patient was hospitalized.

5731091-3 | Diabetic Ketoacidosis
on Apr 21, 2008 Female patient from UNITED STATES , child 4 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). Patient had the following side effects: diabetic ketoacidosis. Elspar dosage: . During the same period patient was treated with PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ). Patient was hospitalized.

5731089-5 | Dehydration, Diabetic Ketoacidosis, Hypoglycaemia, Hypotension, Pyrexia
Patient was taking Elspar (View Usage). After Elspar was administered, patient had the following side effects: dehydration, diabetic ketoacidosis, hypoglycaemia, hypotension, pyrexia on Apr 21, 2008 from UNITED STATES Additional patient health information: Male patient , 18 years of age, was diagnosed with acute lymphocytic leukaemia and. Elspar dosage: . During the same period patient was treated with PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ). Patient was hospitalized.

5731088-3 | Dehydration, Diabetic Ketoacidosis, Hypoglycaemia, Pyrexia
Adverse event was reported on Apr 21, 2008 by a Female patient taking Elspar (View Usage) (Dosage: ) was diagnosed with acute lymphocytic leukaemia and. Location: UNITED STATES , child 3. years of age, Patient experienced the following unwanted or unexpected effects: dehydration, diabetic ketoacidosis, hypoglycaemia, pyrexia. During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ). Patient was hospitalized.

5636720-0 | Infection
on Feb 05, 2008 Male patient from FRANCE , 25 years of age, was diagnosed with t-cell type acute leukaemia and was treated with Elspar (View Usage). Patient had the following side effects: infection (What is infection?). Elspar dosage: . During the same period patient was treated with CORTICOSTEROID (NO PREF. NAME) (View Corticosteroid (no Pref. Name) Review and Corticosteroid (no Pref. Name) Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ).

5608741-5 | Blood Culture Positive, Blood Potassium Abnormal, Deep Vein Thrombosis, Haemoglobin Abnormal, Hypocalcaemia, Infection, Jugular Vein Thrombosis, Lymphopenia, Mouth Ulceration
on Jan 29, 2008 Female patient from UNITED STATES , weighting 160.9 lb, was treated with Elspar (View Usage). After Elspar was administered, patient had the following side effects: blood culture positive, blood potassium abnormal, deep vein thrombosis (What is deep vein thrombosis?), haemoglobin abnormal, hypocalcaemia, infection (What is infection?), jugular vein thrombosis, lymphopenia, mouth ulceration. Elspar dosage: 36000 Million Iu. During the same period patient was treated with METHOTREXATE (400 Mg) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

5605459-X | Blood Culture Positive, Deep Vein Thrombosis, Haemorrhage, Infection, Jugular Vein Thrombosis, Mouth Ulceration, Mucosal Inflammation, Neutrophil Count Decreased, Oral Intake Reduced
Patient was taking Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: blood culture positive, deep vein thrombosis (What is deep vein thrombosis?), haemorrhage, infection (What is infection?), jugular vein thrombosis, mouth ulceration, mucosal inflammation, neutrophil count decreased, oral intake reduced on Jan 24, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 160.9 lb, . Elspar dosage: 36000 Million Iu. During the same period patient was treated with METHOTREXATE (400 Mg) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

5603879-0 | Blood Culture Positive, Deep Vein Thrombosis, Hypocalcaemia, Jugular Vein Thrombosis, Mouth Ulceration, Mucosal Inflammation, Neutrophil Count Abnormal, Pharyngeal Ulceration, Platelet Count Abnormal
Adverse event was reported on Jan 25, 2008 by a Female patient taking Elspar (View Usage) (Dosage: 36000 Million Iu) . Location: UNITED STATES , weighting 160.9 lb, Patient had the following side effects: blood culture positive, deep vein thrombosis (What is deep vein thrombosis?), hypocalcaemia, jugular vein thrombosis, mouth ulceration, mucosal inflammation, neutrophil count abnormal, pharyngeal ulceration, platelet count abnormal. During the same period patient was treated with METHOTREXATE (400 Mg) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

5603400-7 | Blood Cholesterol Increased, Coagulopathy, Hypertriglyceridaemia, Pancreatitis, Plasmapheresis
on Jan 08, 2008 Male patient from ITALY , child 10 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Elspar (View Usage). After Elspar was administered, patient had the following side effects: blood cholesterol increased, coagulopathy, hypertriglyceridaemia, pancreatitis, plasmapheresis. Elspar dosage: Qd;im. During the same period patient was treated with PREDNISONE TAB (60 Mg/m**2;qd) (View Prednisone Tab Review and Prednisone Tab Label ), VINCRISTINE (1.5 Mg/m**2;qd) (View Vincristine Review and Vincristine Label ), DAUNORUBICIN HCL (30 Mg/m**2;qd) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), METHOTREXATE (12 Mg;) (View Methotrexate Review and Methotrexate Label ).

5598148-1 | Mouth Ulceration, Mucosal Inflammation, Pharyngeal Ulceration, Pharyngolaryngeal Pain, Staphylococcal Infection
on Jan 17, 2008 Female patient from UNITED STATES , weighting 160.9 lb, was treated with Elspar (View Usage). Patient experienced the following unwanted or unexpected effects: mouth ulceration, mucosal inflammation, pharyngeal ulceration, pharyngolaryngeal pain, staphylococcal infection (What is staphylococcal infection?). Elspar dosage: 36000 Million Iu. During the same period patient was treated with METHOTREXATE (400 Mg) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

5593248-4 | Blood Culture Positive, Mouth Ulceration, Mucosal Inflammation, Neutrophil Count Abnormal, Pharyngeal Ulceration, Pyrexia, Staphylococcal Infection
Patient was taking Elspar (View Usage). Patient had the following side effects: blood culture positive, mouth ulceration, mucosal inflammation, neutrophil count abnormal, pharyngeal ulceration, pyrexia, staphylococcal infection (What is staphylococcal infection?) on Jan 15, 2008 from UNITED STATES Additional patient health information: Female patient , weighting 160.9 lb, . Elspar dosage: 36000 Million Iu. During the same period patient was treated with METHOTREXATE (400 Mg) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.